Article Sidebar

PDF
Date Published: 07/03/2023
Abstract Views: 633
Views PDF: 249
DOI: https://doi.org/10.51298/vmj.v523i2.4508
Issue
Vol. 523 No. 2 (2023)
Section
Các bài báo
How to Cite
Đỗ, H. K. ., & Nguyễn, T. B. P. . (2023). ASSSESSING TREATMENT RESULTS OF SECOND-LINE PEMBROLIZUMAB FOR THE TREATMENT OF RECURRENT/METASTATIC NON-SMALL CELL LUNG CANCER. Vietnam Medical Journal, 523(2). https://doi.org/10.51298/vmj.v523i2.4508

ASSSESSING TREATMENT RESULTS OF SECOND-LINE PEMBROLIZUMAB FOR THE TREATMENT OF RECURRENT/METASTATIC NON-SMALL CELL LUNG CANCER

Hùng Kiên Đỗ1,, Thị Bích Phượng Nguyễn1
1 National cancer hopsital

Main Article Content

Abstract

Objective: Assessing the treatment results and adverse events of second-line pembrolizumab for the treatment of recurrent/metastatic non-small cell lung cancer patients at National Cancer Hospital from 06/2017 to 10/2022. Patients and method: Retrospective and prospective analyses of 22 patients diagnosed of recurrent/ metastatic non-small cell lung carcinoma treated with second-line pembrolizumab at National Cancer Hospital from 06/2017 to 10/2022. Results: Partial response rate was 31.8%, stable disease rate was 40.9%. Disease-control rate was 72.7%. Mean progression-free survival (PFS) was 5.25±2.22 months (range, 2.25-22 months). There was no significant difference in PFS among patients with clinical and subclinical features. Rates of hyperthyroidism and hypothyroidism were similar, accounted for 9.1% of cases. All grades were grade 1.  Conclusion: Second-line pembrolizumab improved the progression-free survival for the treatment of metastatic non-small lung cancer with a mean PFS of 5.25±2.22 months and disease-control rate was 72.7%.

Article Details

Keywords

Non-small cell lung cancer, recurrent/ metastatic stage, National Cancer Hospital, pembrolizumab monotherapy.

References

1. Berland L, Heeke S, Humbert O, et al. Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. J Thorac Dis. 2019;11(Suppl 1):S71-S80.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
3. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11(6):645-653; quiz 653.
4. Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther. 2013; 13(6):745-758.
5. Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016; 387(10027): 1540-1550.
6. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet. 2014; 384(9948): 1109-1117.
7. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rded: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e341S-e368S.
8. Wang C, Qiao W, Jiang Y, et al. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer. Cancer Med. 2019;8(8):4023-4031.